CTX-PD01 is a CTX’s autologous cell therapy for Parkinson’s disease. Cell therapies offer enormous potential in treating numerous diseases such as neurodegenerative diseases, tissue degradation, metabolic disorders, and cancer. Our stem cell-based treatment, utilizing CTX’s specialized mDAP/mDAN differentiation technology, offers a safe and efficient way to cure for sporadic Parkinson’s disease. This autologous cell therapy for Parkinson’s disease is currently in a preclinical phase of study, evaluating its safety and efficacy using in vivo animal models.

CTX-PD02/03 are a set of combinatorial cell therapies under investigation for Parkinson's disease. Currently in the discovery phase, these therapies aim to boost the functional recovery of transplanted neurons. Candidates are identified through an extensive screening platform, which screens compounds for their ability to enhance neuronal and glial cell function. The selected candidates have shown promise in alleviating neuroinflammation, integrating neural circuits, and promoting the long-term survival of transplanted neurons.

CTX-ED01/02 are CTX’s iPSC-based tissue/cell therapies developed for the treatment of ocular diseases. The 3D corneal epithelial sheet and retina organoid are considered significant sources for grafts in tissue/cell transplantation for multiple eye diseases. Presently, we’re studying this iPSC-based ocular organoid generation process at the concluding step of the discovery stage, aiming to create a more cost- and time-effective methodology.

iPSC-based cell therapy with our CTX-HyiPSC, represents one of the most promising approaches in regenerative medicine. Hypoimmunogenic iPSCs, serving as off-the-shelf products, could facilitate significant advancements in stem cell-based healthcare. We believe our HyiPSC has the potential to drive transformative changes in the field of regenerative medicine

CTX-SCB, our dedicated iPSC bank, focuses on creating and preserving clinical grade iPSCs for personalized stem cell-based healthcare. iPSCs, with their ability to differentiate into various cell types and 3D organoids, represent a significant resource in regenerative medicine, offering solutions for a multitude of medical conditions. Leveraging our expertise and cutting-edge technology, we provide the highest quality iPSC banking services, ensuring patient access to the latest in stem cell-based therapies. CTX-SCB is the optimal choice for your healthcare needs.

CTX's brain organoid, known as a 'mini-brain,' is a 3D tissue model crafted from human iPSCs, possessing a high degree of functional and structural similarity to the human brain. We use a state-of-the-art brain organoid generation system and leverage this platform to model various brain diseases including neurodegenerative diseases, brain damage, brain injury and cancer. In addition, our human iPSC-derived brain organoids can be used for human-specific drug candidate screening and toxicity evaluation, presenting exciting opportunities for future pharmacological advancements.